SCHEMBL9430

SCHEMBL9430

Brc1ccc2ccccc2n1

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NCF1 P14598 3/20 0.52
CYP1A2 P05177 2/20 0.52
NOS2 P35228 1/20 0.52
BACE1 P56817 1/20 0.52
CA12 O43570 1/20 0.52
CA9 Q16790 1/20 0.52
MAPT P10636 3/20 0.48
ALDH1A1 P00352 2/20 0.48
GLA P06280 1/20 0.48
HPGD P15428 1/20 0.48
ACHE P22303 1/20 0.48
NPC1 O15118 5/20 0.46
RAB9A P51151 5/20 0.46
MAPK1 P28482 1/20 0.46
HDAC8 Q9BY41 1/20 0.45
MGAM O43451 1/20 0.45
TDP1 Q9NUW8 1/20 0.45
CYP2A6 P11509 2/20 0.44
AR P10275 2/20 0.43
CYP3A4 P08684 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14127532 1.00 NCF1 (0.52) NCF1CYP1A2NOS2BACE1CA12
SCHEMBL29427043 1.00 NCF1 (0.52) NCF1CYP1A2NOS2BACE1CA12
SCHEMBL28914737 0.97 NCF1 (0.50) NCF1CYP1A2NOS2BACE1CA12
SCHEMBL6347887 0.97 NCF1 (0.50) NCF1CYP1A2NOS2BACE1CA12
SCHEMBL4868283 0.84 TDP1 (0.52) NCF1CYP1A2NOS2BACE1CA12
SCHEMBL28901057 0.80 RAB9A (0.38) NCF1CYP1A2NOS2BACE1CA12
SCHEMBL7512795 0.80 GPBAR1 (0.43) NCF1CYP1A2MAPK1CYP3A4CYP2C9
SCHEMBL30121602 0.78 RAB9A (0.49) NCF1CYP1A2NOS2BACE1CA12
SCHEMBL12446780 0.78 RAB9A (0.49) NCF1CYP1A2NOS2BACE1CA12
SCHEMBL12982905 0.74 NCF1 (0.52) NCF1CYP1A2NOS2BACE1CA12

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1415 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-119285543-B Sulfonylation method of halogenated quinoline and aryl sulfonyl hydrazine 南京工业大学 2026-05-15 CN claimed
CN-120192316-A Biphenyl indoloquinoline structural compound, preparation method and OLED device 成都维拓立柔性电子技术有限公司 2025-06-24 CN claimed
CN-119823038-A Catalyst, preparation method and application thereof 万华化学集团股份有限公司 2025-04-15 CN claimed
CN-119285543-A Sulfonylation method of halogenated quinoline and aryl sulfonyl hydrazine 南京工业大学 2025-01-10 CN claimed
CN-119101915-A Method for constructing benzoxazole [3,2-a ] quinoline salt by utilizing electrochemical oxidative coupling reaction 桂林理工大学 2024-12-10 CN claimed
CN-118239950-A Biphenyl indoloquinoline structural compound, preparation method and OLED device 成都维拓立柔性电子技术有限公司 2024-06-25 CN claimed
CN-117865932-A Preparation method of benzothiophene sulfone compound with medicinal and fluorescent activity 北京化工大学 2024-04-12 CN claimed
US-20240010619-A1 SMALL MOLECULES WITH ANTIBACTERIAL ACTIVITY NEW MEXICO TECH UNIVERSITY RESEARCH PARK CORPORATION 2024-01-11 US claimed
CN-116751221-A Preparation method and application method of novel quinoline-2-borate 西安欧得光电材料有限公司 2023-09-15 CN claimed
CN-114958342-A Three-component doped luminescent material with adjustable phosphorescence performance and preparation method thereof 温州大学新材料与产业技术研究院 2022-08-30 CN claimed
CN-102190676-A Method and apparatus for continuously producing aryl boric acid BAYER TECHNOLOGY AND ENGINEERING SHANGHAI COMPANY LTD 2011-09-21 CN claimed
CN-101948366-A Method for preparing 4- (diphenylamino) biaryl compound in water phase UNIV DALIAN TECH 2011-01-19 CN claimed
CN-101293961-A Electrochromic polymeric compounds, preparing method and application thereof UNIV ZHEJIANG TECHNOLOGY (CN) 2008-10-29 CN claimed
US-6713615-B2 Process for producing erythromycin derivative TAISHO PHARMACEUTICAL CO., LTD. (JP) 2004-03-30 US claimed
US-20030191295-A1 Process for producing erythromycin derivative TAISHO PHARMACEUTICAL CO., LTD. (JP) 2003-10-09 US claimed
CN-1446224-A Process for producing erythromycin derivative TAISHO PHARMACEUTICAL CO LTD (JP) 2003-10-01 CN claimed
EP-1310506-A1 PROCESS FOR PRODUCING ERYTHROMYCIN DERIVATIVE TAISHO PHARMACEUTICAL CO., LTD (JP) 2003-05-14 EP claimed
EP-0365863-B1 Novel quinolyloxazole-2-ones useful as proteinkinase C inhibitors MERRELL DOW PHARMA (US) 1994-08-17 EP claimed
CN-1042145-A New quinolyl  azoles-2-ketone compounds as inhibitors of protein kinase C MERRELL DOW PHARMA (US) 1990-05-16 CN claimed
EP-0365863-A2 Novel quinolyloxazole-2-ones useful as proteinkinase C inhibitors MERRELL DOW PHARMACEUTICALS INC. (US) 1990-05-02 EP claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240010619-A1 SMALL MOLECULES WITH ANTIBACTERIAL ACTIVITY CLPP, MRPL21, TIAL1 NCF1 346/4885CYP1A2 4409/4885NOS2 1529/4885
US-20030191295-A1 Process for producing erythromycin derivative CYP51A1, ERG28, ELOVL6 NCF1 3551/4885CYP1A2 530/4885NOS2 1269/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.